Top Ten most popular articles on this week

pharmafile | May 4, 2018 | News story | Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing BMS, EMA, Kymriah, Novartis, Porton Biopharma, Regeneron, Roche, Sandoz, Sanofi, Shire, Takeda, biosimilars, dementia 

It’s Friday again and it’s been a week busy with companies’ financials. One company’s in particular were of note due to its generics unit’s struggles, in the form of Novartis. It then had some bad news broken shortly after its biosimilar failed to impress the FDA. Luckily, it had some positive news to fall back on after a second indication for its breakthrough CAR-T treatment, Kymriah.

Despite no further movement on the Takeda-Shire deal, there is still an appointment here that will certainly be impacted by the success or failure of it.

Check out the week’s ten most popular articles on now!

10. Sanofi/Regeneron forced to slash price in wake of slow sales

Sanofi and Regeneron have attempted to boost sales of Praluent by agreeing a deal that will see them reduce the price of the medicine to between $4,460 and $7,975, with the shortfall to the list price made up by rebates.

9. BMS pulls the plug on Phase 3 trials of IDO1 inhibitor

Bristol-Myers Squibb has terminated two pivotal Phase 3 trials of BMS-986205, an IDO1 inhibitor, investigating its efficacy in non-small cell lung cancer and head and neck cancer in combination with Opdivo.

8. EMA’s CHMP backs Roche’s Perjeta combo in HER2-positive breast cancer

Roche’s Perjeta has edged one step closer to approval as a combo therapy after the EMA’s CHMP backed its use alongside Herceptin and chemotherapy in the adjuvant treatment of HER2-positive early breast cancer at high risk of recurrence.

7. Novartis becomes first to gain second CAR T indication

Novartis has announced that its CAR T treatment, Kymriah, has successfully been given a second indication for the treatment of relapsed or refractory large B-cell lymphoma after two or more lines of treatment.

6. Sandoz US woes continue with biosimilar rejection

Only adding to its troubles in the US market, Novartis announced that the FDA has issued a complete response later in regards to the unit’s application for its biosimilar GP2013.

5. New study argues the importance of existing anti-inflammatory drugs in fighting dementia

A new study by scientists in Australia has put forward an explanation for why current approaches have failed to produce progress in dementia and Alzheimer’s.

4. Takeda announces new UK MD, ahead of Shire transformation

Jon Neal will take on the role after being promoted internally from his former position as Business Unit Director for Takeda’s UK Oncology unit.

3. Startup CEO who injected untested herpes cure during live stream found dead

Aaron Traywick, who made headlines when he injected himself with an untested DIY herpes vaccine during a live streaming session on Facebook back in February this year, wasbeen found dead at a float spa in Washington DC.

2. Porton Biopharma opens new leukaemia drug production facility

Porton Biopharma Limited officially opened the doors of its new fermentation facility, the principle function of which will be to produce PBL’s leukaemia drug Erwinase.

1. Connecting patients to doctors

Our feature at the beggining of the week featurse Dan Vahdat, CEO and Co-founder of Medopad, discussing the rapid expansion of the app he helped develop, as its mobile health benefits saw it grow swiftly across different therapeutic areas and even continents.

Related Content

Sanofi announce positive phase 2 data for MS drug frexalimab

French pharmaceutical and healthcare company Sanofi have announced positive trial data from its phase 2 …

Is the pharmaceutical sector prepared to face a titanium dioxide ban?

Dr Subhashis Chakraborty, head of Global Product Management, ACG Capsules In the wake of the …

FDA grants Priority Review for Takeda’s cTTP treatment

Japanese biopharmaceutical company Takeda has announced that the US Food and Drug Administration (FDA) has …

Latest content